News
BCRX
8.12
-2.05%
-0.17
Is BioCryst Pharmaceuticals (BCRX) Undervalued After Its Recent Share Price Slide?
Simply Wall St · 1d ago
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity
Seeking Alpha · 2d ago
BioCryst Pharmaceuticals Price Target Cut to $11.00/Share From $13.00 by RBC Capital
Dow Jones · 3d ago
BioCryst Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital
Dow Jones · 3d ago
RBC Capital Downgrades BioCryst Pharma to Sector Perform, Lowers Price Target to $11
Benzinga · 3d ago
BioCryst downgraded to Sector Perform from Outperform at RBC Capital
TipRanks · 3d ago
Ten healthcare stocks with A-rated valuations and strong revenue growth
Seeking Alpha · 4d ago
BioCryst Pharmaceuticals Price Target Maintained With a $16.00/Share by Needham
Dow Jones · 5d ago
Needham Reiterates Buy on BioCryst Pharma, Maintains $16 Price Target
Benzinga · 5d ago
Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)
TipRanks · 5d ago
Weekly Report: what happened at BCRX last week (0831-0904)?
Weekly Report · 6d ago
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
NASDAQ · 09/06 12:50
Does Japan’s First Pediatric ORLADEYO Approval Reshape The Bull Case For BioCryst Pharmaceuticals (BCRX)?
Simply Wall St · 09/04 08:28
BioCryst Pharmaceuticals (BCRX) Wins Japan Pediatric Approval With Undervalued Growth Story In Focus
Simply Wall St · 09/02 13:22
Weekly Report: what happened at BCRX last week (0824-0828)?
Weekly Report · 08/31 09:47
BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve
Seeking Alpha · 08/28 15:59
Weekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal
NASDAQ · 08/28 14:42
Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a Bet
NASDAQ · 08/28 13:55
How Investors Are Reacting To BioCryst (BCRX) Winning Japan’s First Oral Pediatric HAE Approval
Simply Wall St · 08/27 07:21
Intuit, Zoom, Qfin Holdings And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Benzinga · 08/26 12:01
More
Webull provides a variety of real-time BCRX stock news. You can receive the latest news about Biocryst Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310.